Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2^SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2^SK to the tumor microenvironment (TME)

Read more at globenewswire.com